Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphOCYtic leukemia

Abstract


Aim. to analyze the efficacy of RFC (rituximab, fludarabine, and cyclophosphan), FCM (fludarabine, cyclophosphan, and mitoxantrone), and FC (fludarabine and cyclophosphan) treatment programs in patients with chronic lymphocytic leukemia (CLL) in an open-labeled comparative controlled investigation.
Materials and methods. The paper presents the authors' results of treatment in patients with progressive CLL in 2002 to 2007. The study included 229 patients, of them 78 patients received the RFC program, 72 had the FCM program, and 79 had the FC one.
Results. With the use of RFC, a clinically significant therapeutic effect was obtained in 96% of the patients, a complete remission (CR) was in 80% of the primary patients and in 53% of the pretreated patients. When the FCM program was applied, a positive response was noted in 93% of the patients, CR was seen in 75 and 42% of the primary and pretreated patients, respectively. In the treatment of FC, the total effect was 80%, CR was in 41 and 14% of the primary and pretreated patients, respectively.
Conclusion. Comparative analysis of an objective response to therapy has indicated that the effectiveness of the RFC significantly exceeds that of the FCM and FC programs, without enhancing toxicity, which allows he RFC regimen to be regarded as the program of choice in therapy for CLL.

About the authors

Tamara Pavlovna Zagoskina

Email: zagoskina@blood.kirov.ru

Sergey Borisovich Tkachenko

Email: DOC4200@yandex.ru

Marina Evgen'evna Golubeva

Email: megolubeva@mail.ru

Alevtina Vasil'evna Kudryavtseva

Email: zagoskina@blood.kirov.ru

Natal'ya Vasil'evna Isaeva

Email: zagoskina@blood.kirov.ru

Ol'ga Viktorovna Malykh

Email: zagoskina@blood.kirov.ru

T P Zagoskina

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

S B Tkachenko

Russian Medical Academy of Postgraduate Education

Russian Medical Academy of Postgraduate Education

M E Golubeva

Town Hematology Center

Town Hematology Center

A V Kudryavtseva

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

N V Isayeva

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

O V Malykh

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

Kirov Research Institute of Hematology and Blood Transfusion, Russian Agency for Medical Technologies

References

  1. Tothova E., Kafkova A., Fricova M. et al. Fludarabine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Neoplasma 2003; 50: 433-437.
  2. Eichhorst B. F., Busch R., Hopfinger G. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
  3. Abbott B. L. Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment. Oncologist 2006; 11 (1): 21- 30.
  4. Bellosillo В., Villamor N. et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1998; 94: 2836-2843.
  5. Bosch F., Ferrer A., Lopez-Guillermo A. et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br. J. Haematol. 2002; 119: 976-984.
  6. Keating M., O'Brien S., Albitar M. et al. Early results of chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituxmab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005; 23: 4079-4088.
  7. Wierda W., O'Brien S., Wen S. et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2005; 23: 4070-4078.
  8. Byrd J. C., Kitada S., Flinn I. W. et al. The mechanism of tumor cell clearence by rituximab in vivo in patients with B-cell chronic lymphocytic leucaemia evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-1043.
  9. Bannerji R., Kitada S., Flinn I. W. et al. Apoptotic regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relatonship to in vivo rituximab resistance. J. Clin. Oncol. 2003; 21: 1466-1471.
  10. Di Gaetano N., Gitteria E., Nota R. et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003; 171: 1581-1587.
  11. Cheson B. D., Bennett J. M., Grever M. et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
  12. Bosh F., Montserrat E. Refining prognostic factors in chronic lymphocytic leukemia. Rev. Clin. Exp. Hematol. 2002; 6 (4): 335-349, 449-450.
  13. Montillo M., Hamblin Т., Hallek M. et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005; 90 (3): 391-399.
  14. Montserrat E. New prognostic markers in CLL. Hematology 2006; 279-284.
  15. Wierda W. G., O'Brien S., Wang X. et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109 (11): 4679-4685.
  16. Sayala H. A., Rawstron A. S., Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. 2007; 20: 499-512.

Statistics

Views

Abstract - 72

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2010 Zagoskina T.P., Tkachenko S.B., Golubeva M.E., Kudryavtseva A.V., Isaeva N.V., Malykh O.V., Zagoskina T.P., Tkachenko S.B., Golubeva M.E., Kudryavtseva A.V., Isayeva N.V., Malykh O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies